Ledermann, Jonathan A <br/><br/>
Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial.  [electronic resource] 

 -  The Lancet. Oncology  Nov 2016 
 - 1579-1589 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial 
<br/><br/><label>ISSN: </label>1474-5488 
<br/><br/><label>Standard No.: </label>10.1016/S1470-2045(16)30376-X  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antineoplastic Agents--therapeutic use<br/>BRCA1 Protein--genetics<br/>BRCA2 Protein--genetics<br/>Cystadenocarcinoma, Serous--drug therapy<br/>Double-Blind Method<br/>Female<br/>Humans<br/>Middle Aged<br/>Mutation<br/>Neoplasm Recurrence, Local--drug therapy<br/>Ovarian Neoplasms--drug therapy<br/>Phthalazines--adverse effects<br/>Piperazines--adverse effects<br/>Poly(ADP-ribose) Polymerase Inhibitors--therapeutic use